ReviewJournal, genetic engineering & biotechnology2026
A review on Mitragyna alkaloids pharmacology, biosynthesis and biotechnological insights.
Review in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitragyna species, known for their diverse traditional uses across various Asian countries, have gained scientific interest due to their pharmacological properties and rich phytochemical composition. This paper presents an updated overview of nine Mitragyna species that are Mitragyna speciosa, M. diversifolia, M. stipulosa, M. rubrostipulata, M. inermis, M. hirsuta, M. parvifolia, M. rotundifolia and M. tubulosa focusing on their ethnobotany, pharmacological properties, and phytochemical constituents since 2022 to 2024. Moreover, we have extensively reviewed all aspects of plant biotechnological approaches of Mitragyna species till date and updated the indole alkaloids biosynthesis and synthetic biology of kratom alkaloids. Pharmacological studies of indole alkaloids especially mitragynine, rhynchophylline and isorhynchophylline showed potential effects on the central nervous system, cardiovascular system, digestive system and peripheral nervous system. Phytochemical analysis has revealed several secondary metabolites, particularly alkaloids, along with other compounds contributing to their medicinal properties. Understanding biosynthesis pathways and employing biotechnological approaches, such as media manipulation, precursor feeding, plant growth regulators, and elicitation, offer promising opportunity for understanding indole alkaloids metabolism and enhancing alkaloid production. Furthermore, metabolic engineering and synthetic biology of mitragyna alkaloids can provide a more sustainable, consistent and scalable alternative which holds significant potential in scientific research and pharmaceutical developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.